drugset / Trial / NCT04158102

Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects

NCT04158102

Phase 1 Completed 20 enrolled Nuance Pharma (shanghai) Co., Ltd
NaSingle-groupOpen-labelOther

Summary

This is a single-center, open-label, single-dose study to evaluate the safety, pharmacokinetics in healthy subjects

Timeline

Start
2019-11-07
Primary completion
2019-12-17
Completion
2019-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 266 mg Subcutaneous

Indications

No indication recorded.